From: Timely HAART initiation may pave the way for a better viral control
ID | Therapy†| Elapsed days ‡ | Days on therapy | Days out therapy | At diagnosis* | At first interruption | ||||
---|---|---|---|---|---|---|---|---|---|---|
 |  |  |  |  | CD4 | CD8 | vRNA | CD4 | CD8 | vRNA |
Pt 03 | D4T,3TC,IDV | 14 | 1775 | 27 | 653 | 1659 | 75 | 809 | 459 | 5794 |
Pt 05 | AZT,3TC,IDV | 61 | 1657 | 27 | 444 | 633 | 100 | 867 | 476 | < 50 |
Pt 29 | AZT,3TC,NFV | 14 | 1069 | 28 | 1103 | 1964 | 31 | 741 | 844 | < 50 |
Pt 33 | AZT,3TC,IDV | 66 | 925 | 28 | 424 | 991 | 0.13 | 458 | 474 | 147 |
Pt 35 | AZT,3TC,EFV | 1 | 1041 | 30 | 522 | 1205 | 78 | 919 | 607 | 496 |
Pt 37 | AZT,3TC,EFV | 0 | 1371 | 790 | 545 | 1233 | 3.9 | 901 | 384 | < 50 |
Pt 58 | AZT,3TC,EFV | 3 | 442 | 27 | 768 | 1632 | 50 | 1451 | 1580 | < 50 |
Pt 06 | AZT,3TC,IDV | 32 | 1620 | 1908 | 882 | 4146 | 4.1 | 754 | 726 | < 50 |
Pt 18 | AZT,3TC,IDV | 26 | 635 | 213 | 1319 | 1810 | 15 | 1718 | 825 | < 80 |
Pt 24 | AZT,3TC,IDV | 3 | 1231 | 542 | 507 | 3162 | 78 | 513 | 1067 | < 50 |
Pt 31 | AZT,3TC,EFV | 19 | 1102 | 1654 | 322 | 243 | 490 | 1154 | 1165 | < 50 |
Pt 41 | AZT,3TC,EFV | 12 | 705 | 1837 | 568 | 278 | 130 | 1326 | 940 | < 50 |
Pt 45 | AZT,3TC,EFV | 5 | 488 | 55 | 307 | 1032 | 130 | 872 | 506 | < 50 |
Pt 53 | AZT,3TC,Lop/rit | 16 | 503 | 179 | 341 | 779 | 18.9 | 545 | 529 | 150 |
Pt 04 | AZT,3TC,IDV | 6 | 1561 | 2155 | 603 | 1288 | 1.6 | 1047 | 1015 | 88 |
Pt 19 | AZT,3TC,IDV | 13 | 1480 | 1640 | 1338 | 716 | 10 | 1113 | 447 | < 50 |
Pt 28 | AZT,3TC,NFV | 7 | 325 | 70 | 281 | 860 | 190 | 863 | 485 | < 80 |
Pt 32 | AZT,3TC,EFV | 15 | 1384 | 669 | 409 | 1448 | 4.3 | 960 | 331 | < 50 |
Pt 72 | AZT,3TC,LPV | 7 | 318 | 343 | 827 | 386 | 19 | 1005 | 751 | < 50 |
Pt 81 | AZT,3TC,NVP | 33 | 745 | 317 | 412 | 264 | 32.5 | 522 | 461 | 68 |
Pt 85 | AZT,3TC,Lop/rit | 46 | 717 | 717 | 326 | 669 | 50 | 855 | 1436 | < 50 |
Pt 92 | 3TC,Lop/rit,TNF | 0 | 455 | 331 | 616 | 3774 | 46.3 | 1027 | 913 | < 50 |